Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation

Menachem Bitan, Kwang Woo Ahn, Heather R. Millard, Michael A. Pulsipher, Hisham Abdel-Azim, Jeffery J. Auletta, Valerie Brown, Ka Wah Chan, Miguel Angel Diaz, Andrew Dietz, Marta González Vincent, Gregory Guilcher, Gregory A. Hale, Robert J. Hayashi, Amy Keating, Parinda Mehta, Kasiani Myers, Kristin Page, Tim Prestidge, Nirali N. ShahAngela R. Smith, Ann Woolfrey, Elizabeth Thiel, Stella M. Davies, Mary Eapen

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We studied leukemia-free (LFS) and overall survival (OS) in children with acute myeloid (AML, n = 790) and acute lymphoblastic leukemia (ALL, n = 1096) who underwent transplantation between 2000 and 2010 and who survived for at least 1 year in remission after related or unrelated donor transplantation. Analysis of patient-, disease-, and transplantation characteristics and acute and chronic graft-versus-host disease (GVHD) was performed to identify factors with adverse effects on LFS and OS. These data were used to develop risk scores for survival. We did not identify any prognostic factors beyond 4 years after transplantation for AML and beyond 3 years for ALL. Risk score for survival for AML includes age, disease status at transplantation, cytogenetic risk group, and chronic GVHD. For ALL, the risk score includes age at transplantation and chronic GVHD. The 10-year probabilities of OS for AML with good (score 0, 1, or 2), intermediate (score 3), and poor risk (score 4, 5, 6, or 7) were 94%, 87%, and 68%, respectively. The 10-year probabilities of OS for ALL were 89% and 80% for good (score 0 or 1) and poor risk (score 2), respectively. Identifying children at risk for late mortality with early intervention may mitigate some excess late mortality.

Original languageEnglish (US)
Pages (from-to)1523-1530
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume23
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Homologous Transplantation
Leukemia
Transplantation
Survival
Graft vs Host Disease
Unrelated Donors
Mortality
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cytogenetics

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Bitan, Menachem ; Ahn, Kwang Woo ; Millard, Heather R. ; Pulsipher, Michael A. ; Abdel-Azim, Hisham ; Auletta, Jeffery J. ; Brown, Valerie ; Chan, Ka Wah ; Diaz, Miguel Angel ; Dietz, Andrew ; Vincent, Marta González ; Guilcher, Gregory ; Hale, Gregory A. ; Hayashi, Robert J. ; Keating, Amy ; Mehta, Parinda ; Myers, Kasiani ; Page, Kristin ; Prestidge, Tim ; Shah, Nirali N. ; Smith, Angela R. ; Woolfrey, Ann ; Thiel, Elizabeth ; Davies, Stella M. ; Eapen, Mary. / Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. In: Biology of Blood and Marrow Transplantation. 2017 ; Vol. 23, No. 9. pp. 1523-1530.
@article{00d5c7e39b074ed696812a3931a3ddd4,
title = "Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation",
abstract = "We studied leukemia-free (LFS) and overall survival (OS) in children with acute myeloid (AML, n = 790) and acute lymphoblastic leukemia (ALL, n = 1096) who underwent transplantation between 2000 and 2010 and who survived for at least 1 year in remission after related or unrelated donor transplantation. Analysis of patient-, disease-, and transplantation characteristics and acute and chronic graft-versus-host disease (GVHD) was performed to identify factors with adverse effects on LFS and OS. These data were used to develop risk scores for survival. We did not identify any prognostic factors beyond 4 years after transplantation for AML and beyond 3 years for ALL. Risk score for survival for AML includes age, disease status at transplantation, cytogenetic risk group, and chronic GVHD. For ALL, the risk score includes age at transplantation and chronic GVHD. The 10-year probabilities of OS for AML with good (score 0, 1, or 2), intermediate (score 3), and poor risk (score 4, 5, 6, or 7) were 94{\%}, 87{\%}, and 68{\%}, respectively. The 10-year probabilities of OS for ALL were 89{\%} and 80{\%} for good (score 0 or 1) and poor risk (score 2), respectively. Identifying children at risk for late mortality with early intervention may mitigate some excess late mortality.",
author = "Menachem Bitan and Ahn, {Kwang Woo} and Millard, {Heather R.} and Pulsipher, {Michael A.} and Hisham Abdel-Azim and Auletta, {Jeffery J.} and Valerie Brown and Chan, {Ka Wah} and Diaz, {Miguel Angel} and Andrew Dietz and Vincent, {Marta Gonz{\'a}lez} and Gregory Guilcher and Hale, {Gregory A.} and Hayashi, {Robert J.} and Amy Keating and Parinda Mehta and Kasiani Myers and Kristin Page and Tim Prestidge and Shah, {Nirali N.} and Smith, {Angela R.} and Ann Woolfrey and Elizabeth Thiel and Davies, {Stella M.} and Mary Eapen",
year = "2017",
month = "9",
day = "1",
doi = "10.1016/j.bbmt.2017.05.011",
language = "English (US)",
volume = "23",
pages = "1523--1530",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "9",

}

Bitan, M, Ahn, KW, Millard, HR, Pulsipher, MA, Abdel-Azim, H, Auletta, JJ, Brown, V, Chan, KW, Diaz, MA, Dietz, A, Vincent, MG, Guilcher, G, Hale, GA, Hayashi, RJ, Keating, A, Mehta, P, Myers, K, Page, K, Prestidge, T, Shah, NN, Smith, AR, Woolfrey, A, Thiel, E, Davies, SM & Eapen, M 2017, 'Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation', Biology of Blood and Marrow Transplantation, vol. 23, no. 9, pp. 1523-1530. https://doi.org/10.1016/j.bbmt.2017.05.011

Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. / Bitan, Menachem; Ahn, Kwang Woo; Millard, Heather R.; Pulsipher, Michael A.; Abdel-Azim, Hisham; Auletta, Jeffery J.; Brown, Valerie; Chan, Ka Wah; Diaz, Miguel Angel; Dietz, Andrew; Vincent, Marta González; Guilcher, Gregory; Hale, Gregory A.; Hayashi, Robert J.; Keating, Amy; Mehta, Parinda; Myers, Kasiani; Page, Kristin; Prestidge, Tim; Shah, Nirali N.; Smith, Angela R.; Woolfrey, Ann; Thiel, Elizabeth; Davies, Stella M.; Eapen, Mary.

In: Biology of Blood and Marrow Transplantation, Vol. 23, No. 9, 01.09.2017, p. 1523-1530.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation

AU - Bitan, Menachem

AU - Ahn, Kwang Woo

AU - Millard, Heather R.

AU - Pulsipher, Michael A.

AU - Abdel-Azim, Hisham

AU - Auletta, Jeffery J.

AU - Brown, Valerie

AU - Chan, Ka Wah

AU - Diaz, Miguel Angel

AU - Dietz, Andrew

AU - Vincent, Marta González

AU - Guilcher, Gregory

AU - Hale, Gregory A.

AU - Hayashi, Robert J.

AU - Keating, Amy

AU - Mehta, Parinda

AU - Myers, Kasiani

AU - Page, Kristin

AU - Prestidge, Tim

AU - Shah, Nirali N.

AU - Smith, Angela R.

AU - Woolfrey, Ann

AU - Thiel, Elizabeth

AU - Davies, Stella M.

AU - Eapen, Mary

PY - 2017/9/1

Y1 - 2017/9/1

N2 - We studied leukemia-free (LFS) and overall survival (OS) in children with acute myeloid (AML, n = 790) and acute lymphoblastic leukemia (ALL, n = 1096) who underwent transplantation between 2000 and 2010 and who survived for at least 1 year in remission after related or unrelated donor transplantation. Analysis of patient-, disease-, and transplantation characteristics and acute and chronic graft-versus-host disease (GVHD) was performed to identify factors with adverse effects on LFS and OS. These data were used to develop risk scores for survival. We did not identify any prognostic factors beyond 4 years after transplantation for AML and beyond 3 years for ALL. Risk score for survival for AML includes age, disease status at transplantation, cytogenetic risk group, and chronic GVHD. For ALL, the risk score includes age at transplantation and chronic GVHD. The 10-year probabilities of OS for AML with good (score 0, 1, or 2), intermediate (score 3), and poor risk (score 4, 5, 6, or 7) were 94%, 87%, and 68%, respectively. The 10-year probabilities of OS for ALL were 89% and 80% for good (score 0 or 1) and poor risk (score 2), respectively. Identifying children at risk for late mortality with early intervention may mitigate some excess late mortality.

AB - We studied leukemia-free (LFS) and overall survival (OS) in children with acute myeloid (AML, n = 790) and acute lymphoblastic leukemia (ALL, n = 1096) who underwent transplantation between 2000 and 2010 and who survived for at least 1 year in remission after related or unrelated donor transplantation. Analysis of patient-, disease-, and transplantation characteristics and acute and chronic graft-versus-host disease (GVHD) was performed to identify factors with adverse effects on LFS and OS. These data were used to develop risk scores for survival. We did not identify any prognostic factors beyond 4 years after transplantation for AML and beyond 3 years for ALL. Risk score for survival for AML includes age, disease status at transplantation, cytogenetic risk group, and chronic GVHD. For ALL, the risk score includes age at transplantation and chronic GVHD. The 10-year probabilities of OS for AML with good (score 0, 1, or 2), intermediate (score 3), and poor risk (score 4, 5, 6, or 7) were 94%, 87%, and 68%, respectively. The 10-year probabilities of OS for ALL were 89% and 80% for good (score 0 or 1) and poor risk (score 2), respectively. Identifying children at risk for late mortality with early intervention may mitigate some excess late mortality.

UR - http://www.scopus.com/inward/record.url?scp=85020896551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020896551&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2017.05.011

DO - 10.1016/j.bbmt.2017.05.011

M3 - Article

C2 - 28527984

AN - SCOPUS:85020896551

VL - 23

SP - 1523

EP - 1530

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 9

ER -